Wellington Management Group LLP Grows Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Wellington Management Group LLP grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,110,407 shares of the biopharmaceutical company’s stock after acquiring an additional 174,482 shares during the period. Wellington Management Group LLP’s holdings in Alnylam Pharmaceuticals were worth $635,296,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Geode Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 6.1% during the 4th quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company’s stock valued at $1,056,884,000 after buying an additional 151,480 shares in the last quarter. Norges Bank purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth $895,816,000. Orbis Allan Gray Ltd increased its holdings in Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after acquiring an additional 486,489 shares in the last quarter. Legal & General Group Plc raised its position in Alnylam Pharmaceuticals by 8.3% during the fourth quarter. Legal & General Group Plc now owns 961,496 shares of the biopharmaceutical company’s stock worth $382,339,000 after acquiring an additional 73,716 shares during the period. Finally, AQR Capital Management LLC raised its position in Alnylam Pharmaceuticals by 23.6% during the fourth quarter. AQR Capital Management LLC now owns 919,959 shares of the biopharmaceutical company’s stock worth $365,822,000 after acquiring an additional 175,951 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 0.2%

Shares of Alnylam Pharmaceuticals stock opened at $237.10 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The stock’s 50 day simple moving average is $262.62 and its 200-day simple moving average is $293.73. The stock has a market cap of $31.73 billion, a P/E ratio of 44.07 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 1-year low of $197.81 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same quarter last year, the firm earned ($0.51) earnings per share. The business’s revenue for the quarter was up 66.9% on a year-over-year basis. Analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by insiders.

Analysts Set New Price Targets

ALNY has been the topic of several research analyst reports. Royal Bank Of Canada dropped their target price on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Barclays reduced their price target on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a research report on Monday, August 3rd. Citigroup decreased their price target on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating on the stock in a research note on Monday, August 3rd. HC Wainwright cut their price objective on Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Finally, Raymond James Financial raised Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 target price for the company in a report on Monday, August 3rd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $386.14.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.